✨ Free AI Report
Pacira BioSciences, Inc.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research Pacira BioSciences, Inc.
Company Research

Pacira BioSciences, Inc.: Business Overview, Financials & Competitive Analysis

Pacira BioSciences, Inc. scores 6/10 on the AskCyborg Cyborg Score (Solid). Growing non-opioid pain management leader with strong gross margins and market opportunity, but execution challenges and profitability constraints require monitoring. Products benefitted over 2.5 million patients in 2025, generating $726 million in revenue with highest gross margins in company history. However, net margin is relatively low at 2.99%, indicating.

What is Pacira BioSciences, Inc.'s industry? Pacira BioSciences, Inc. (pacira.com) operates in Biopharmaceutical - Specialty Pain Management / Non-Opioid Therapeutics. AskCyborg classifies Pacira BioSciences, Inc. under Biopharmaceutical - Specialty Pain Management / Non-Opioid Therapeutics in its company registry.

Pacira BioSciences delivers innovative, non-opioid pain therapies with three commercial-stage non-opioid treatments and a novel gene therapy asset advancing to treat large prevalent diseases like osteoarthritis. The c...

6/ 10Solid

Cyborg Score thesis

Growing non-opioid pain management leader with strong gross margins and market opportunity, but execution challenges and...

Read the full analyst-debate transcript →
Industry Biopharmaceutical - Specialty Pain Management / Non-Opioid Therapeutics
3 named competitors
3 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: September 14, 2026
AI-Verified Research
30+ Page Report

Get the Latest Pacira BioSciences, Inc. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Analyst-debate audio for Pacira BioSciences, Inc.

AskCyborg analysts argue the bull and bear cases for Pacira BioSciences, Inc. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
What's in This Report
Pacira BioSciences, Inc. OverviewStrategic ProfileCompetitive LandscapeIndustry ContextKey facts
Get Interactive Report Freeor start reading below

Pacira BioSciences, Inc. Overview

Pro stress-test →

Pacira BioSciences delivers innovative, non-opioid pain therapies with three commercial-stage non-opioid treatments and a novel gene therapy asset advancing to treat large prevalent diseases like osteoarthritis. The company focuses on transforming patient outcomes through locally-administered pain management solutions in a market driven by the opioid crisis and shift toward safer alternatives.

Strategic Profile

Pro stress-test →

Pacira projects 77-79% gross margins for 2026, driven by success of its flagship product EXPAREL, which benefits from increased reimbursement, wider commercial use, and intellectual property protection extending into the 2040s. The company is expanding market reach through strategic partnerships and enhanced intellectual property protection.

Competitive Landscape

Pro stress-test →

Competitors include Grifols, Noven Pharmaceuticals, Tris Pharma, Pfizer Pakistan, and Pfizer Manufacturing Austria. Pacira holds a leading position in non-opioid local pain management with strong IP protection, facing competition from larger pharma players and alternative pain management technologies.

Industry Context

Pacira BioSciences, Inc. operates in Biopharmaceutical - Specialty Pain Management / Non-Opioid Therapeutics.

Key facts

Founded: 2006 · Headquarters: Tampa, Florida, US · Revenue: $726.4M · Market cap: $962M

What the analysts stress-tested

The top findings that survived the multi-agent debate for Pacira BioSciences, Inc..

  • EXPAREL, flagship product, generated $575.1 million in net product sales in 2025, up 5% year-over-year
  • Company executing five-by-30 growth strategy with disciplined capital deployment
+2 more stress-tested counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • February 2026Q4 2025 earnings reported $196.9M quarterly revenue (up 5% YoY) with 2026 guidance of $745-$770M total revenue
  • February 2026Filed lawsuit dismissal; added seasoned board member Samit Hirawat
  • +1 moreTrack every material event for Pacira BioSciences, Inc. as it happens. Explore monitoring →
Get alerted when Pacira BioSciences, Inc. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

Noven PharmaceuticalsTransdermal pain management and specialty pharma→GrifolsHealthcare solutions and biopharmaceuticals→Alternative technologiesNeuromodulation and device-based pain management→

Compare Pacira BioSciences, Inc. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Pacira BioSciences, Inc. operates in Biopharmaceutical - Specialty Pain Management / Non-Opioid Therapeutics. See how the rest of the sector scores on the Cyborg framework.

Browse Biopharmaceutical - Specialty Pain Management / Non-Opioid Therapeutics research →
NEW · MCP server

Ask your AI assistant about Pacira BioSciences, Inc.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Pacira BioSciences, Inc. and its top competitor on Cyborg Score”
“What did Pacira BioSciences, Inc. do this quarter?”
“Is Pacira BioSciences, Inc. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg builds confidence

⚔

Analyst debate, not single-author opinion

Every report is stress-tested by a panel of AI analysts arguing across 11 dimensions. The output is the part of the case that survived pushback.

📊

Recalibrated weekly

The Cyborg Score is recomputed weekly against fresh data. Recent material developments are continuously tracked and surfaced.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The same company gets the same score from any analyst running the framework.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, news flow, and proprietary analyst signals. Read the methodology →

Frequently asked questions

What does Pacira BioSciences, Inc. do?+
Pacira BioSciences delivers innovative, non-opioid pain therapies with three commercial-stage non-opioid treatments and a novel gene therapy asset advancing to treat large prevalent diseases like osteoarthritis. The c...
What is Pacira BioSciences, Inc.'s Cyborg Score?+
Pacira BioSciences, Inc. has a Cyborg Score of 6/10 (Solid). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Pacira BioSciences, Inc.'s main competitors?+
Named competitors include Noven Pharmaceuticals, Grifols, Alternative technologies. The full competitive landscape is in the AskCyborg report.
How can I get the full Pacira BioSciences, Inc. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Pacira BioSciences, Inc. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Pacira BioSciences, Inc. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

More Biopharmaceutical - Specialty Pain Management research

Companies in the same sector and named competitors, ranked by Cyborg Score.

6Pacira BioSciences, Inc.5Grifols, S.A.